Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleOncology

Feasibility of 18F-FDG Dose Reductions in Breast Cancer PET/MRI

Bert-Ram Sah, Soleen Ghafoor, Irene A. Burger, Edwin E.G.W. ter Voert, Tetsuro Sekine, Gaspar Delso, Martin Huellner, Konstantin J. Dedes, Andreas Boss and Patrick Veit-Haibach
Journal of Nuclear Medicine December 2018, 59 (12) 1817-1822; DOI: https://doi.org/10.2967/jnumed.118.209007
Bert-Ram Sah
1Department of Nuclear Medicine, University Hospital of Zurich, Zurich, Switzerland
2Department of Cancer Imaging, King`s College London, London, United Kingdom
3Department of Diagnostic and Interventional Radiology, University Hospital of Zurich, Zurich, Switzerland
4University of Zurich, Zurich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Soleen Ghafoor
3Department of Diagnostic and Interventional Radiology, University Hospital of Zurich, Zurich, Switzerland
4University of Zurich, Zurich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Irene A. Burger
1Department of Nuclear Medicine, University Hospital of Zurich, Zurich, Switzerland
4University of Zurich, Zurich, Switzerland
5Cancer Center Zurich, Zurich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edwin E.G.W. ter Voert
1Department of Nuclear Medicine, University Hospital of Zurich, Zurich, Switzerland
4University of Zurich, Zurich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tetsuro Sekine
1Department of Nuclear Medicine, University Hospital of Zurich, Zurich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gaspar Delso
1Department of Nuclear Medicine, University Hospital of Zurich, Zurich, Switzerland
6GE Healthcare, Waukesha, Wisconsin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Huellner
1Department of Nuclear Medicine, University Hospital of Zurich, Zurich, Switzerland
4University of Zurich, Zurich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Konstantin J. Dedes
5Cancer Center Zurich, Zurich, Switzerland
7Department of Gynaecology, University Hospital of Zurich, Zurich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas Boss
3Department of Diagnostic and Interventional Radiology, University Hospital of Zurich, Zurich, Switzerland
4University of Zurich, Zurich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick Veit-Haibach
1Department of Nuclear Medicine, University Hospital of Zurich, Zurich, Switzerland
3Department of Diagnostic and Interventional Radiology, University Hospital of Zurich, Zurich, Switzerland
4University of Zurich, Zurich, Switzerland
8Joint Department of Medical Imaging, University Health Network, Toronto, Ontario, Canada; and
9University of Toronto, Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Abstract

The goal of this study was to determine the level of clinically acceptable 18F-FDG dose reduction in time-of-flight PET/MRI in patients with breast cancer. Methods: Twenty-six consecutive women with histologically proven breast cancer were analyzed (median age, 51 y; range, 34–83 y). Simulated dose-reduced PET images were generated by unlisting the list-mode data on PET/MRI. The acquired 20-min PET frame was reconstructed in 5 ways: a reconstruction of the first 2 min with 3 iterations and 28 subsets for reference, and reconstructions simulating 100%, 20%, 10%, and 5% of the original dose. General image quality and artifacts, image sharpness, image noise, and lesion detectability were analyzed using a 4-point scale. Qualitative parameters were compared using the nonparametric Friedman test for multiple samples and the Wilcoxon signed-rank test for paired samples. Different groups of independent samples were compared using the Mann–Whitney U test. Results: Overall, 355 lesions (71 lesions with 5 different reconstructions each) were evaluated. The 20-min reconstruction with 100% injected dose showed the best results in all categories. For general image quality and artifacts, image sharpness, and noise, the reconstructions with a simulated dose of 20% and 10% were significantly better than the 2-min reconstructions (P ≤ 0.001). Furthermore, 20%, 10%, and 5% reconstructions did not yield results different from those of the 2-min reconstruction for detectability of the primary lesion. For 10% of the injected dose, a calculated mean dose of 22.6 ± 5.5 MBq (range, 17.9–36.9 MBq) would have been applied, resulting in an estimated whole-body radiation burden of 0.5 ± 0.1 mSv (range, 0.4–0.7 mSv). Conclusion: Ten percent of the standard dose of 18F-FDG (reduction of ≤90%) results in clinically acceptable PET image quality in time-of-flight PET/MRI. The calculated radiation exposure would be comparable to the effective dose of a single digital mammogram. A reduction of radiation burden to this level might justify partial-body examinations with PET/MRI for dedicated indications.

  • dose reduction
  • positron emission tomography
  • magnetic resonance
  • image reconstruction
  • breast cancer

Footnotes

  • Published online Jun. 7, 2018.

  • © 2018 by the Society of Nuclear Medicine and Molecular Imaging.
View Full Text
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 59 (12)
Journal of Nuclear Medicine
Vol. 59, Issue 12
December 1, 2018
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Feasibility of 18F-FDG Dose Reductions in Breast Cancer PET/MRI
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Feasibility of 18F-FDG Dose Reductions in Breast Cancer PET/MRI
Bert-Ram Sah, Soleen Ghafoor, Irene A. Burger, Edwin E.G.W. ter Voert, Tetsuro Sekine, Gaspar Delso, Martin Huellner, Konstantin J. Dedes, Andreas Boss, Patrick Veit-Haibach
Journal of Nuclear Medicine Dec 2018, 59 (12) 1817-1822; DOI: 10.2967/jnumed.118.209007

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Feasibility of 18F-FDG Dose Reductions in Breast Cancer PET/MRI
Bert-Ram Sah, Soleen Ghafoor, Irene A. Burger, Edwin E.G.W. ter Voert, Tetsuro Sekine, Gaspar Delso, Martin Huellner, Konstantin J. Dedes, Andreas Boss, Patrick Veit-Haibach
Journal of Nuclear Medicine Dec 2018, 59 (12) 1817-1822; DOI: 10.2967/jnumed.118.209007
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology

  • Chimeric antigen receptor (CAR) T cells Imaging: Clinical Needs and Strategies for Success
  • Metastatic NUT Midline Carcinoma
  • Radionuclides used in Nuclear Therapeutic Medicine: a brief history, properties and main relevant studies of radionuclides with mass number less than 100
Show more Oncology

Clinical

  • TauIQ: A Canonical Image Based Algorithm to Quantify Tau PET Scans
  • Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker
  • Addition of 131I-MIBG to PRRT (90Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors
Show more Clinical

Similar Articles

Keywords

  • dose reduction
  • Positron Emission Tomography
  • Magnetic Resonance
  • Image Reconstruction
  • breast cancer
SNMMI

© 2025 SNMMI

Powered by HighWire